62 results about "Bacterial composition" patented technology

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention relates to a bactericidal composition containing fluxapyroxad and thiediazole copper. The bacterial composition is compounded from fluxapyroxad and thiediazole copper in a binary mode, wherein a mass ratio of fluxapyroxad to thiediazole copper is (1-50) to (50-1); a mass fraction of fluxapyroxad and thiediazole in the preparation is 1%-80%, and the rest of the preparation is auxiliary components which are allowed to use and are acceptable in a pesticide. A dosage form of the bactericidal composition is missible oil, a suspending agent, wettable powder, a water dispersible granule, emulsion in water, microemulsion, a granule and a micro-capsule. The bactericidal composition is mainly used for controlling plant gray mold, peronospora and phytophthora germs.

The present invention is based on the demonstration that bacteria of the Akkermansia genus improve the response to CAR T-cells therapy. According to the invention, Akkermansia bacteria are administered to patients treated with CAR T-cells, especially if their gut microbiome was devoid of such bacteria before administering said CAR T-cells.

The present disclosure discloses a method for improving, treating and / or preventing mild to moderate chronic kidney disease (CKD) in a subject, comprising administrating one or two bacteria selected from Bacteroides eggerthii and Phocaeicola plebeius (or Bacteroides plebeius).

The present application relates to probiotic compositions, e.g., comprising at least one bacterial strain selected from: Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium infantis, or from Streptococcus thermophiles, Lactobacillus acidophilus, Lactobacillus plantarum, and Lactobacillus paracasei, and methods for use thereof.

Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising a bacterial consortium that promotes interferon (IFN) response in the gut microbiome of a subject and enhances the anti-tumor effects of certain immune checkpoint inhibitor (ICI) therapies. In some embodiments, the compositions are useful for treating a subject having cancer.

The present invention relates to the use of a bacterial composition having an arginine deaminase activity (inhibition of nitric oxide synthase by converting L-arginine to L-citrulline) of 11,000 μmol L-citrulline / h / g of composition and a sphingomyelinase (ceramide production) activity of 0.01-1,000 nanomoles ceramide / h / g of composition in the treatment and / or prevention of respiratory tract diseases caused by viruses such as influenza viruses, coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (RSV), rhinoviruses, pneumoviruses, or respiratory failure induced or exacerbated by viral infection, angina pectoris, cor pulmonale, dyspnea, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure, Pickwickian syndrome, pulmonary hypertension, pneumonia, or even cystic fibrosis (CF) exacerbated by viral infection.

Use of a composition comprising bacteria for odor reduction in the treatment of symptoms of tissue necrosis, wound secretions or putrid wounds or a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis; wherein the composition comprises the bacteria Lactobacillus acidophilus TYCA15, Lactobacillus salivarius, Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum in the ratio 1:1:1:1:1; and the composition totals 10 9 bacteria per gram of the composition.

The invention relates to a polynucleotide comprising a lacZ gene (lacZFS) encoding a β-galactosidase characterized by a particular profile with respect to its lactose hydrolysis efficiency. The invention also relates to a strain of Streptococcus thermophilus comprising a lacZFS allele and a bacterial composition thereof, and its use for obtaining fermented milk that does not undergo subsequent acidification.

Provided herein are bacterial compositions that are useful for treating and / or preventing a chronic liver disease, neutropenia, and / or a disease or disorder associated with a solid organ transplantation. In some aspects, treating and / or preventing comprises treating an infection complication due to a chronic liver disease, neutropenia, and / or a solid organ transplantation. The bacterial compositions disclosed herein are designed to exhibit one or more functional features that are useful for the treatment of such diseases and disorders.

The invention relates to a bacterial strain, a composition and application of the bacterial strain and the composition in preventing and treating plant diseases and promoting plant growth. In one aspect, there is provided an isolated bacterial strain RR15 of Pantoea (preserved in Australian National Metrology Research Institute on June 9, 2022 with a preservation number of V22 / 011015). Also provided are methods for utilizing the bacterial strains and compositions to promote plant growth, promote plant tuber growth, inhibit pathogen-induced plant root infection, and inhibit pathogen-induced plant root disease.

Disclosed herein are bacterial compositions and methods for treating neurological disorders, improving brain function, and reducing stress.

The present disclosure relates to a method and composition for improving at least one plant-related parameter in cucurbitaceous the method comprising: contacting a plant or plant part with an amount of at least one bacterium, the at least one bacterium, the amount of said at least one bacterium being effective to provide an improvement in said at least one plant-related parameter. Also disclosed is a kit comprising the at least one bacterium and instructions for use of the at least one bacterium for improving at least one plant-related parameter in cucurbitaceous.

The novel invention is based, at least in part. on the surprising finding that the combination of bacterial strains comprising P. freudenreichii JS27 and B. longum subsp. infantis, particularly B. longum subsp. infantis TPY12-1 can be used in medicine and / or as a food supplement when grown simultaneously. As such and as shown in the description and appended examples, growth and viability of bacterial strains possessing synergistic behavior can be enhanced in the human gut and thus can increase bioavailability as compared with alternative combinations of bacteria.

The application discloses a di(2-ethylhexyl) phthalate degrading bacterium, a bacterial composition and application thereof. The degrading bacterium is named Sphingomonas parapaucimobilis GHQ28 and Stenotrophomonas maltophilia GHQ31. Research finds that GHQ28 and GHQ31 have chemotaxis to DEHP and downstream metabolites thereof, and there is a synergistic interaction between the two bacteria; the growth and DEHP degradation speed of the two strains under co-culture conditions are faster than that under single culture conditions. The bacterial composition composed of the two strains has a highest degradation rate of 99.2±0.59% to 400mg / L DEHP within 72h, compared with single culture, the total biomass is increased by 1.4-50.3 times, and the DEHP degradation rate is increased by 1.07-58.82 times. The application provides a new technical means for remediation of DEHP contaminated soil or water.

The present invention consists in combining low dose intestinal radiation (ILDR) with immunotherapy or other antineoplastic treatments, in the ideal context of intestinal presence or prevalence of Christensenellaceae family members, especially for solid cancers at an advanced stage (refractory to first line chemo or immunotherapy). The invention also pertains to a bacterial composition,e.g. comprising Chistensenella bacteria, for use in the treatment of cancer in a patient, in combination with intestinal low dose radiotherapy (ILDR) and an antineoplastic treatment.

Disclosed herein, are compositions comprising Bacteroides uniformis or Blautia sp, and methods of treating gastrointestinal distress, inflammatory bowel disease, as well as preventing weight loss or maintain weight or increasing colon length by administering the compositions to a subject.

The present application relates to probiotic compositions comprising two or more bacterial strains selected from: Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophiles, Lactobacillus acidophilus, Lactobacillus plantarum, and Lactobacillus paracasei.

The invention provides a pseudomonas bacterium composition, a complex microbial inoculant and application of the pseudomonas bacterium composition and the complex microbial inoculant, and belongs to the technical field of microorganisms. The invention provides a Pseudomonas bacteria combination, which comprises Pseudomonas bacteria JF1 and Pseudomonas hutmensis JF2, the Pseudomonas bacteria JF1 and the Pseudomonas hutmensis JF2 are growth-promoting bacteria screened from rhizosphere soil of rhizoma corydalis, and the Pseudomonas bacteria JF1 and the Pseudomonas bacteria JF2 have the capabilities of dissolving phosphorus and producing siderophores, can be used as growth promoting agents in a synergistic manner to promote the growth of rhizoma corydalis seedlings, and can be used for promoting the growth of rhizoma corydalis seedlings. The method has a remarkable effect of promoting accumulation of the total alkaloid content in rhizoma corydalis tubers, can be used for artificial cultivation of rhizoma corydalis, provides a theoretical basis for improving the yield and quality of rhizoma corydalis, and has important guiding significance for reasonably and effectively utilizing microorganisms to improve the quality and yield of Qinshi medicine-rhizoma corydalis.

The present invention is directed, inter alia, to compositions comprising a population of at least one strain of bacteria at least partially attached to particles, the particles comprise (i) a polysaccharide-based material; and (ii) a metal carbonate. Uses of the compositions, e.g., for prevention or treatment of dysbiosis, and methods for the preparation thereof are further provided herein.

The present invention is directed to a method of treating a substance-use disorder (SUD) in a subject in need thereof, including administering to the subject a therapeutically effective amount of a pharmaceutical composition including bacteria, wherein at least 50% of the bacteria belong to a bacterial family being any one of: Ruminococcaceae, Rikenellaceae, and both, such as R. gnavus.

The invention relates to a polynucleotide comprising a lacZ gene (lacZFS) encoding a β-galactosidase characterized by a particular profile regarding its efficiency of hydrolysis of lactose. The invention is also directed to a Streptococcus thermophilus strain comprising a lacZFS allele and bacterial composition thereof, and their use to obtain fermented milk not undergoing post-acidification.

Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.

Provided herein are bacterial compositions that are useful for treating and preventing complications and side effects associated with a disease or disorder, such as those associated with dysbiosis of a gastrointestinal tract. The bacterial compositions disclosed herein are designed to exhibit one or more functional features that are useful for the treatment of such diseases and disorders.

The invention provides a method for obtaining one or more supporting bacteria for a bacterial composition. The invention further provides devices and kits, which may be used in such methods, and uses of such devices and kits. Such supporting bacteria may be suitable for formation of synthetic bacterial consortia.

The present invention relates to bacterial strains and compositions, and their use for controlling diseases in plants and for promoting plant growth. In one aspect, the isolated bacterial strain RR15 of the genus Pantoea, deposited under Accession Number V22 / 011015 on 9 June 2022 with the National Measurement Institute, Australia, is provided. Methods for promoting plant growth, promoting plant tuber growth, inhibiting plant root infection by a pathogen, and inhibiting plant root disease by a pathogen, using the bacterial strains and compositions are also provided

An Acinetobacter pittii strain is provided, which is Acinetobacter pittii FL3-2 with a deposit number of CCTCC NO: M20232618. A bacterial composition is provided, which includes the Acinetobacter pittii FL3-2 as an active component. A method for phosphorus removal from a sewage sample is also provided, in which the Acinetobacter pittii FL3-2 is inoculated into the to-be-treated sewage sample.

A bacterial composition for substrate inoculation to improve fertility of the substrate includes a predetermined concentration of at least one strain of autotrophic bacteria, wherein the autotrophic bacteria is characterised in having the ability to produce organic compounds in a predetermined substrate; and a predetermined concentration of at least one strain of mineral nutrient producing bacteria selected from a group including diazotrophic bacteria, potassium solubilizing bacteria and phosphate solubilizing bacteria, wherein the bacteria is characterised in having the ability to produce mineral nutrients in such predetermined substrate. The substrate inoculation of the autotrophic bacterial portion of the composition increases production of metabolizable forms of organic compounds, and inoculation of the mineral nutrient producing bacterial portion of the composition metabolizes the increased organic compounds for an increased production of metabolizable forms of mineral nutrients in the predetermined substrate.

The present disclosure relates to a bacterial composition, a method of producing a bacterial composition and various uses of the bacterial composition.

Escherichia coli is a widely studied model organism and an integral component of the human gut microbiome, offering significant potential for bacteria-based therapeutic applications. However, engineering native E. coli strains poses persistent challenges. In this study, the chassis- independent recombinase-assisted genome engineering technique was leveraged to engineer the native gut strain E. coli EcAZ-1 and the probiotic strain E. coli Nissle 1917 (EcN). The bioluminescent lux operon, green fluorescent protein (GFP), and the oxygen-independent fluorescent protein IFP 2.0 were successfully introduced into both strains. To further enhance IFP 2.0 fluorescence, a heme oxygenase was co-expressed, and the chromophore biliverdin was supplemented, achieving robust IFP 2.0 expression under both anaerobic and aerobic conditions. Also, both strains were engineered to biosynthesize bioactive compounds, including the plant- derived flavonoid naringenin and mycosporine-like amino acids. The results underscore the potential of native E. coli strains as flexible and robust platforms for synthetic biology, enabling novel applications in biomedical research and therapeutics. Based on these results, this application provides recombinant bacteria generating IFP2.0 fluorescence under anaerobic condition, bacterial composition for gastrointestinal cancer detection and use method thereof, and naringenin or MAA overproducing recombinant bacteria.